# ROS-Fueled Allies: STAT3, PKM2, and HIF-1α Influencing Energy Metabolism in Hormone-Independent Cancers

## TL;DR

This study explores how the STAT3–PKM2–HIF-1α/ROS signaling pathway drives aggressive hormone-independent breast and prostate cancers by altering their metabolism.

## Contribution

The study identifies a novel regulatory axis involving STAT3, PKM2, and HIF-1α fueled by ROS in hormone-independent cancers.

## Key findings

- Pharmacological inhibition of STAT3 and ROS scavenging reduced phosphorylated STAT3, PKM2 nuclear translocation, and HIF-1α stabilization.
- Treated cells showed decreased ROS, lactate production, and a shift toward oxidative phosphorylation.
- Reduced Ki-67 expression and impaired clonogenic capacity were observed in treated cells.

## Abstract

Hormone-independent breast and prostate cancers represent highly aggressive malignancies characterized by profound metabolic reprogramming, elevated oxidative stress, and loss of sensitivity to endocrine therapies. Increasing evidence indicates that tumor progression and metabolic plasticity are sustained by interconnected signaling networks linking transcriptional regulation to energy metabolism. Among these, the STAT3–PKM2–HIF-1α signaling axis, functionally reinforced by reactive oxygen species (ROS), has been proposed as a central regulator of the Warburg phenotype and cellular adaptation to adverse microenvironmental conditions. Using androgen-independent prostate cancer (DU145) and triple-negative breast cancer (KPL-4) cell lines, we demonstrated constitutive activation and reciprocal regulation of STAT3, PKM2, and HIF-1α. Pharmacological inhibition of STAT3, stabilization of tetrameric PKM2 by L-serine, and ROS scavenging with N-acetylcysteine significantly reduced STAT3 phosphorylation, PKM2 nuclear translocation, and HIF-1α stabilization. These molecular effects were accompanied by decreased intracellular ROS levels, reduced lactate production, increased pyruvate levels, and a metabolic shift toward oxidative phosphorylation. Functionally, treated cells exhibited reduced Ki-67 expression and impaired clonogenic capacity. Our results identify the STAT3–PKM2–HIF-1α/ROS axis as a key determinant of metabolic and phenotypic plasticity in hormone-independent breast and prostate cancers, highlighting its potential as a molecular target for therapeutic modulation of cancer-associated metabolic phenotypes.